Logo image of ALNOV.PA

NOVACYT (ALNOV.PA) Stock Fundamental Analysis

EPA:ALNOV - FR0010397232 - Common Stock

0.452 EUR
0 (-0.88%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, ALNOV scores 3 out of 10 in our fundamental rating. ALNOV was compared to 70 industry peers in the Biotechnology industry. ALNOV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALNOV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALNOV has reported negative net income.
In the past year ALNOV has reported a negative cash flow from operations.
In the past 5 years ALNOV reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ALNOV reported negative operating cash flow in multiple years.
ALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFALNOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

ALNOV's Return On Assets of -59.12% is on the low side compared to the rest of the industry. ALNOV is outperformed by 68.92% of its industry peers.
With a Return On Equity value of -87.21%, ALNOV perfoms like the industry average, outperforming 48.65% of the companies in the same industry.
Industry RankSector Rank
ROA -59.12%
ROE -87.21%
ROIC N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ALNOV.PA Yearly ROA, ROE, ROICALNOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

With an excellent Gross Margin value of 163.39%, ALNOV belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
ALNOV's Gross Margin has improved in the last couple of years.
ALNOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 163.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
ALNOV.PA Yearly Profit, Operating, Gross MarginsALNOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

ALNOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALNOV has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALNOV has more shares outstanding
Compared to 1 year ago, ALNOV has a worse debt to assets ratio.
ALNOV.PA Yearly Shares OutstandingALNOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALNOV.PA Yearly Total Debt VS Total AssetsALNOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ALNOV has an Altman-Z score of 0.66. This is a bad value and indicates that ALNOV is not financially healthy and even has some risk of bankruptcy.
ALNOV has a Altman-Z score (0.66) which is in line with its industry peers.
A Debt/Equity ratio of 0.22 indicates that ALNOV is not too dependend on debt financing.
ALNOV has a better Debt to Equity ratio (0.22) than 62.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 0.66
ROIC/WACCN/A
WACC6.87%
ALNOV.PA Yearly LT Debt VS Equity VS FCFALNOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

ALNOV has a Current Ratio of 6.33. This indicates that ALNOV is financially healthy and has no problem in meeting its short term obligations.
ALNOV's Current ratio of 6.33 is amongst the best of the industry. ALNOV outperforms 85.14% of its industry peers.
A Quick Ratio of 5.97 indicates that ALNOV has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.97, ALNOV belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.33
Quick Ratio 5.97
ALNOV.PA Yearly Current Assets VS Current LiabilitesALNOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ALNOV have decreased strongly by -49.44% in the last year.
The Revenue has grown by 84.82% in the past year. This is a very strong growth!
ALNOV shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.35% yearly.
EPS 1Y (TTM)-49.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
Revenue 1Y (TTM)84.82%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%27.82%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNOV.PA Yearly Revenue VS EstimatesALNOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALNOV.PA Yearly EPS VS EstimatesALNOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2020 2021 2022 2023 2024 0 0.5 -0.5 1 1.5 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALNOV. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNOV.PA Price Earnings VS Forward Price EarningsALNOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNOV.PA Per share dataALNOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALNOV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVACYT

EPA:ALNOV (9/5/2025, 7:00:00 PM)

0.452

0 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)09-25 2025-09-25
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners0.19%
Ins Owner ChangeN/A
Market Cap31.92M
Analysts37.14
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.41
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.32
BVpS0.78
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.12%
ROE -87.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 163.39%
FCFM N/A
ROA(3y)-32.84%
ROA(5y)-9.46%
ROE(3y)-47.33%
ROE(5y)-12.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y75.01%
GM growth 5Y20.62%
F-Score4
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 9.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.33
Quick Ratio 5.97
Altman-Z 0.66
F-Score4
WACC6.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.93%
Cap/Sales(5y)4.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-49.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)84.82%
Revenue growth 3Y-40.37%
Revenue growth 5Y11.35%
Sales Q2Q%27.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.4%
OCF growth 3YN/A
OCF growth 5YN/A